New treatment may address imatinib-resistant tumors

Each year, 3,000 to 6,000 people are diagnosed with gastrointestinal stromal tumor (GIST)—the most common sarcoma of the gastrointestinal tract. Imatinib myeslate, or Gleevec®, has proved to be a...

2017 Biomedical Innovation Program Drug Discovery awards announced

Two drug discovery projects have been named recipients of the 2017 Biomedical Innovation Program awards. The awards program is a collaboration of the Oregon Clinical & Translational Research...

OHSU breaks ground on cancer research facility

OHSU broke ground June 16 on its newest building, the 320,000-square-foot Knight Cancer Institute research facility on the South Waterfront. Located north of the Collaborative Life Sciences Building,...